Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

doi:10.1245/s10434-023-14416-0

Editorial

. 2024 Jan;31(1):1-3.

doi: 10.1245/s10434-023-14416-0. Epub 2023 Oct 16.

Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

Alexander C J van Akkooi^{1

2

3}

Affiliations

¹ Melanoma Institute Australia, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.
² Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.
³ Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.

PMID: 37843663
DOI: 10.1245/s10434-023-14416-0

Editorial

Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

Alexander C J van Akkooi. Ann Surg Oncol. 2024 Jan.

. 2024 Jan;31(1):1-3.

doi: 10.1245/s10434-023-14416-0. Epub 2023 Oct 16.

Author

Alexander C J van Akkooi^{1

2

3}

Affiliations

¹ Melanoma Institute Australia, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.
² Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.
³ Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.

PMID: 37843663
DOI: 10.1245/s10434-023-14416-0

No abstract available

PubMed Disclaimer

Cited by

The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status.
An S, Li W, Do H, Kwon HY, Kim B, Kim K, Kim Y, Cho MY. An S, et al. Biomedicines. 2024 Mar 28;12(4):752. doi: 10.3390/biomedicines12040752. Biomedicines. 2024. PMID: 38672108 Free PMC article.
Overview of current melanoma therapies.
Fateeva A, Eddy K, Chen S. Fateeva A, et al. Pigment Cell Melanoma Res. 2024 Sep;37(5):562-568. doi: 10.1111/pcmr.13154. Epub 2023 Dec 8. Pigment Cell Melanoma Res. 2024. PMID: 38063139 Review.
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.
Su J, Fu Y, Cui Z, Abidin Z, Yuan J, Zhang X, Li R, Zhao C. Su J, et al. Front Pharmacol. 2024 Jan 10;14:1349081. doi: 10.3389/fphar.2023.1349081. eCollection 2023. Front Pharmacol. 2024. PMID: 38269271 Free PMC article. Review.

References

1. Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55. - DOI - PubMed - PMC
1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. - DOI - PubMed - PMC
1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. - DOI - PubMed - PMC
1. Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389–98. - DOI - PubMed
1. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

[1] Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55. - DOI - PubMed - PMC

[2] Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55. - DOI - PubMed - PMC

[3] Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. - DOI - PubMed - PMC

[4] Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. - DOI - PubMed - PMC

[5] Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. - DOI - PubMed - PMC

[6] Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. - DOI - PubMed - PMC

[7] Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389–98. - DOI - PubMed

[8] Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389–98. - DOI - PubMed

[9] Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. - DOI - PubMed

[10] Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

Affiliations

Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

Author

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical